Back to News
Market Impact: 0.45

DXCM Quantitative Stock Analysis

DXCMNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechTechnology & Innovation
DXCM Quantitative Stock Analysis

Validea's guru fundamental report indicates that Dexcom Inc. (DXCM) receives a high rating (88%) based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram, specifically excelling in areas such as book/market ratio, return on assets, and cash flow metrics; however, the company fails the research and development to assets test. Mohanram's model identifies growth stocks with sustained future growth using financial statement analysis, differentiating winners from losers among low book-to-market stocks.

Analysis

Dexcom Inc. (DXCM) has received a notably high rating of 88% from Validea's P/B Growth Investor model, a strategy developed by Partha Mohanram designed to identify low book-to-market stocks with characteristics indicative of sustained future growth. This rating signifies considerable interest in the stock based on the model's criteria. DXCM successfully met eight key fundamental tests, including book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, sales variance, advertising to assets, and capital expenditures to assets. However, the company did not pass the 'Research and Development to Assets' criterion. Mohanram's academic research, which underpins this model, focuses on distinguishing high-performing growth stocks from underperformers through rigorous financial statement analysis, lending credibility to this positive assessment despite the single noted failure.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.75

Ticker Sentiment

DXCM0.75
NDAQ0.00

Key Decisions for Investors

  • Investors may consider DXCM as a candidate for growth-oriented portfolios, given its high score on a recognized growth stock selection model and its strong performance across multiple fundamental metrics.
  • Further due diligence is warranted regarding the 'Research and Development to Assets' metric, as understanding the implications of this specific shortfall is crucial for assessing long-term growth sustainability in the medical equipment sector.
  • Monitor DXCM's future financial statements to ensure continued alignment with the growth characteristics highlighted by the Mohanram model, particularly in areas where it currently excels and any changes to its R&D investment profile.